1. Evaluation of alpha-II-spectrin breakdown products as potential biomarkers for early recognition and severity of aneurysmal subarachnoid hemorrhage
- Author
-
Stephen B. Lewis, Linda Papa, Kimberly Rosenthal, John C. Axley, Jared M. Kelly, and Francesca Silvestri
- Subjects
Ventriculostomy ,Adult ,Male ,medicine.medical_specialty ,Subarachnoid hemorrhage ,medicine.medical_treatment ,lcsh:Medicine ,Gastroenterology ,Disease-Free Survival ,Article ,03 medical and health sciences ,0302 clinical medicine ,Cerebrospinal fluid ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,lcsh:Science ,Survival rate ,Aged ,Multidisciplinary ,business.industry ,Trauma center ,lcsh:R ,Spectrin ,030208 emergency & critical care medicine ,Middle Aged ,Subarachnoid Hemorrhage ,medicine.disease ,Clinical trial ,Survival Rate ,Predictive value of tests ,Female ,lcsh:Q ,business ,030217 neurology & neurosurgery ,Biomarkers - Abstract
This study assessed whether cytoskeletal protein alpha-II spectrin breakdown products (SBDP150, SBDP145, and SBDP120) would identify the presence of aSAH and be associated with severity (GCS score, WFNS grade and survival to hospital discharge). This prospective case-control study, conducted at a tertiary care Level I trauma center, enrolled adult patients with angiography confirmed aSAH who underwent ventriculostomy placement for cerebrospinal fluid (CSF) drainage. There were 40 patients enrolled in the study, 20 with aSAH and 20 control subjects. Patients with aSAH were a mean age of 54 (SD15) and 75% were female. There were significant differences in SBDP150, SBDP145, and SBDP120 CSF levels between patients with and without aSAH (p
- Published
- 2018